From Executive Director Peter Waite, Canadian Hereditary Angioedema Network:
The Canadian Hereditary Angioedema Network has updated its 2014 Canadian Hereditary Angioedema Guideline with an expanded scope to include the management of HAE patients worldwide. It is a collaboration of Canadian and international HAE experts and patient groups led by the Canadian Hereditary Angioedema Network. The objective of this guideline is to provide evidence-based recommendations, using the GRADE system, for the management of patients with HAE. This includes the treatment of attacks, short-term prophylaxis, longterm prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and comprehensive care. New to the 2019 version of this guideline are sections covering the diagnosis and recommended therapies for acute treatment in HAE patients with normal C1-INH, as well as sections on pregnant and paediatric patients, patient associations and an HAE registry.
The Guideline was published electronically in the Allergy, Asthma & Clinical Immunology Journal – please see https://aacijournal.biomedcentral.com/articles/10.1186/s13223-019-0376-8.
